Stage 4 CKD, Hyperkalemia, and a Medication List That Needs Editing

Stop or change now:

• Ibuprofen - the highest-yield intervention. NSAIDs cause afferent arteriolar vasoconstriction, worsen AKI-on-CKD, bloat potassium, blunt the antihypertensive effect of the ACE inhibitor, and cause fluid retention. Chronic use at this eGFR is untenable.
• Spironolactone - a mineralocorticoid receptor antagonist layered on an ACE inhibitor in a patient with eGFR 22 and K⁺ 5.6 mEq/L is a predictable cause of hyperkalemia. Stop it.
• Metformin - contraindicated at eGFR <30 mL/min/1.73 m² because of lactic acidosis risk, especially with a bicarbonate of 20 mEq/L.

Do not reflexively stop:

• Lisinopril. ACE inhibition is his best available kidney and cardiovascular protection given albuminuria of 1,200 mg/g. The sequence matters: remove the NSAID and the MRA first, counsel on dietary potassium, add a potassium binder, and recheck in 1–2 weeks. If K⁺ remains >5.5 despite that, reduce the dose or accept a partial reduction rather than abandoning the drug outright. A creatinine rise up to ~30% after ACE-inhibitor initiation or dose change is expected and not a reason to stop.
• Atorvastatin is appropriate and should continue; cardiovascular risk is his dominant mortality risk.

This is chronic, non-emergent hyperkalemia in a patient with a normal ECG and no symptoms, so the treatment is a sustained-lowering strategy rather than an emergency protocol.

• No IV calcium, no acute insulin/glucose or albuterol - those are for hyperkalemia with ECG changes or K⁺ roughly >6.5 mEq/L, and their effect is transient.
• Remove the offending agents (above), which alone may resolve it.
• Dietary potassium counseling with a renal dietitian.
• Potassium binder - patiromer or sodium zirconium cyclosilicate - to allow continued renin-angiotensin blockade. This is the key modern move: the binder exists so the ACE inhibitor does not have to be sacrificed.
• Address the metabolic acidosis (bicarbonate 20 mEq/L); correcting acidosis reduces potassium and may slow CKD progression. A loop diuretic is useful only if there is volume overload, which he does not have.
• Recheck potassium and creatinine in 1–2 weeks.

Escalate to urgent evaluation/ECG if K⁺ rises above ~6.0–6.5, if the ECG shows peaked T waves or QRS widening, or if he develops weakness or palpitations. Refractory hyperkalemia despite these measures is itself an indication for kidney replacement therapy.

Answer honestly and with structure, because the answer is 'not yet, but we should start preparing.'

Why not yet:

• Dialysis is started for a clinical indication, not an eGFR number. The accepted triggers are refractory hyperkalemia, refractory acidosis, volume overload unresponsive to diuretics, uremic pericarditis or encephalopathy, and some toxin poisonings. He currently has none - he is asymptomatic without edema.
• His eGFR of 22 is stage 4, not stage 5, and the trajectory (30 → 22 over a year) may partly reflect the NSAID and volume rather than pure progression.

What determines timing and preparation:

• The kidney failure risk equation gives a 2- and 5-year probability of needing replacement therapy; it is more informative than eGFR alone and is used to time referral and access planning.
• Referral to nephrology (already indicated at eGFR <30, and driven by KFRE risk) and education about modality choice - hemodialysis, peritoneal dialysis, conservative management - plus transplant evaluation.
• Vascular access planning should begin roughly when eGFR falls below ~15 or when 2-year risk is high, because a fistula needs months to mature.
• Address modifiable accelerants now: NSAID cessation, glycemic and blood pressure control, avoiding nephrotoxins and contrast where possible, and treating his anemia of CKD.